Medically Assisted Reproduction: Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R01)

The summary for the Medically Assisted Reproduction: Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Medically Assisted Reproduction: Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R01): Assisted Reproductive Technologies (ART) and Non-IVF Fertility Treatments (NIFT) have revolutionized the field of human reproduction for the past 3 decades. Millions of children have been born worldwide through the utilization of these technologies.An analysis of the long-term outcomes in the children is crucial for understanding the inherent risks or benefits of these procedures.The outcomes of children conceived after ART include data from nationally-maintained registries in different countries around the world. There is no uniformity in the collection and analysis of data, and most registries lack information on long-term health and developmental outcomes. NIFT has been in use for much longer than ART, and there is lack of national registries for outcomes of NIFT across the world. Long-term biological, physical, and social outcomes of offspring conceived by ART or NIFT may be different depending upon the methods or approaches used in ART or NIFT. The underlying cause of parental infertility may also contribute to the outcomes. This funding opportunity announcement encourages the extramural scientific community to submit applications to study ART and NIFT for their potential long-term health and developmental outcomes.

Federal Grant Title:	Medically Assisted Reproduction: Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-14-272
Type of Funding:	Grant
CFDA Numbers:	93.865
CFDA Descriptions:	Child Health and Human Development Extramural Research
Current Application Deadline:	Sep 30, 2016
Original Application Deadline:	Sep 30, 2016
Posted Date:	Jul 3, 2014
Creation Date:	Jul 3, 2014
Archive Date:	Oct 31, 2016
Total Program Funding:
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: County governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
City or township governments
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
State governments
Independent school districts
Native American tribal governments (Federally recognized)
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Special district governments
Private institutions of higher education
Public housing authorities/Indian housing authorities
Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-14-272.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allo...; • National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 C...; • Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescen...; • Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed); • Biological Testing Facility (X01 Clinical Trial Not Allowed); • Phase II Small Business Technology Transfer Renewal Awards for Device Assessment or Precli...; • Phase II Small Business Innovation Research Renewal Awards for Device Assessment or Precli...; • Reproductive Genetics and Epigenetics
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...